BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36633913)

  • 21. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
    Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
    J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.
    Liu J; Shen H; Huang S; Lin J; Yan Z; Qian G; Lu Z; Wan X; Zhang F; Wang K; Zhang Y; Li J
    World J Surg Oncol; 2023 Feb; 21(1):42. PubMed ID: 36765340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis.
    Jang JW; Choi JY; Kim YS; Woo HY; Choi SK; Lee CH; Kim TY; Sohn JH; Tak WY; Han KH
    Hepatology; 2015 Jun; 61(6):1809-20. PubMed ID: 25627342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
    Wu X; Zhou J; Sun Y; Ding H; Chen G; Xie W; Piao H; Xu X; Jiang W; Ma H; Ma A; Chen Y; Xu M; Cheng J; Xu Y; Meng T; Wang B; Chen S; Shi Y; Kong Y; Ou X; You H; Jia J
    Hepatol Int; 2021 Feb; 15(1):82-92. PubMed ID: 33460002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated hepatitis B virus RNA levels in HBeAg-positive patients with low-level viraemia or previous low-level viraemia.
    Li T; Chen Y; Zhang Y; Wu S; Zhang L; Wang L
    J Viral Hepat; 2024 Jun; ():. PubMed ID: 38855857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Natural history of chronic hepatitis B virus infection under low-level viremia].
    Yan MM; Sun LH
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):322-326. PubMed ID: 37137862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
    Lok AS; Perrillo R; Lalama CM; Fried MW; Belle SH; Ghany MG; Khalili M; Fontana RJ; Sterling RK; Terrault N; Feld JJ; Di Bisceglie AM; Lau DTY; Hassan M; Janssen HLA;
    Hepatology; 2021 Jun; 73(6):2124-2140. PubMed ID: 32936969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
    J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations.
    Yang JH; Zhang H; Chen XB; Chen G; Wang X
    World J Gastroenterol; 2013 Jun; 19(24):3861-5. PubMed ID: 23840126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
    J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma.
    Huang S; Xia Y; Lei Z; Zou Q; Li J; Yang T; Wang K; Yan Z; Wan X; Shen F
    J Am Coll Surg; 2017 Mar; 224(3):283-293.e4. PubMed ID: 27923614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients.
    Tian Y; Fan Z; Xu L; Cao Y; Chen S; Pan Z; Gao Y; Li H; Zheng S; Ma Y; Duan Z; Zhang X; Ren F
    Emerg Microbes Infect; 2023 Dec; 12(1):e2177088. PubMed ID: 36735916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West.
    Allaire M; El Hajj W; Brichler S; Diallo K; Fanica D; Blaise L; Nkontchou G; Grando V; Arbadi F; Nahon P; Ziol M; Nault JC; Ganne-Carrié N
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101436. PubMed ID: 32418851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.